Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
María E. Ruiz, Melisa E. Gantner and Alan Talevi
Affiliation: Biopharmacy, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata (UNLP) – Argentinean National Council for Scientific and Technical Research (CONICET) CCT La Plata. 47 and 115, La Plata (B1900AJI), Buenos Aires, Argentina.
The great efforts of many researchers have brought down some of the barriers that exist to turn a good in vitro
compound into a potential in vivo drug. The advent of pharmaceutical nanotechnology has allowed an arsenal of drugs
with poor stability, low solubility, high off-target toxicity and other disadvantageous features, to be accessible as pharmaceutical
products that could be administered to a patient. Nanotechnology was introduced in drug delivery very long ago,
but has flourished with unprecedented intensity during the last twenty years and now a diversity of nano-based preparations
are at clinical stage of development or already available in the market. Undoubtedly, nanotechnology plays a key
role in future pharmaceutical development and pharmacotherapy. In the first part of this review, we have already discussed
recent (2008-2012) patents on linear polymer-based nanosystems (nanogels, nanospheres and nanocapsules) applications
to cancer therapy. Here, we have expanded such analysis to branched polymers (dendrimers), self-assembling
nanomicelles and lipid-based nanocarriers.
Keywords: Anticancer drug therapy, dendrimers, lipid-based nanosystems, liposomes, micelles, nanostructured lipid carriers,
patents, solid lipid nanocarriers.
Rights & PermissionsPrintExport